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ABSTRACT

THE EFFECTS OF INCREASED CAMP LEVELS ON NEURONAL
DIFFERENTIATION IN MURINE EMBRYONIC STEM CELLS, AND THE
CREATION OF A CRISPR-INDUCED C.1252C>T POINT MUTATION IN THE
ADCY5 GENE
Elizabeth Zepeda
ADCY5-related dyskinesia is a rare movement disorder with early onset in
childhood and adolescence. Previous studies linked this disease to various point
mutations in the ADCY5 gene. Recent studies show that two of the point mutations cause
an increase in cyclic adenosine monophosphate (cAMP) levels. However, it remains
unknown how increased levels of cAMP result in the phenotypes associated with this
disease. My study examines the effects of increased cAMP levels on neuronal
differentiation of mouse embryonic stem cells (mESCs). My experiments demonstrated
successful differentiation of mESCs into the dopaminergic neuronal lineage, indicated by
the presence of Tuj 1 (a class III beta-tubulin neuronal cell marker), and tyrosine
hydroxylase (TH) (an enzyme found in dopaminergic neurons), as detected by
immunocytochemistry (ICC). To determine the effect of cAMP on this process, murine
embryonic stem cells were differentiated in the presence of a range of db-cAMP
concentrations. Cells treated with 700 µM of db-cAMP during the differentiation step of
the protocol showed increased percentage of the neuronal cell-type, followed by a
decrease in percent neuronal-cell type treated with 1400 µM and 2800 µM db-cAMP.
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There was no significant effect of db-cAMP on percent dopamine-containing neurons. In
addition, there were lower levels of tyrosine hydroxylase (TH) protein present in the
membrane fraction, in cells treated with 1400 µM db-cAMP compared to no treatment,
and no significant change in cytosolic TH. My results also revealed an increase in
dopamine receptor D2 in both the membrane and cytosol. In order to characterize the
effects of the point mutation p.R418W on cellular cAMP levels in HEK293T cells, I
attempted to create a mutation in a HEK293T cell line using CRISPR. Once the mutant
cell line was generated, the plan was to treat with pharmacological agonists to betaadrenergic receptors to stimulate cAMP production in mutated cells as well as control
cells. The amount of cAMP produced in mutated cells versus wild-type would then be
quantified using enzyme-linked immunosorbent assay (ELISA). After the first round,
CRISPR failed to produce the desired mutation, the guide RNA was modified, and the
process repeated three times. Although we successfully created the desired edit in the
third round, other mutations directly flanking upstream and downstream predicted that
ADCY5 protein would be non-functional, so the ELISA was not performed. Overall our
results provide a model of the molecular basis of ADCY5 related-dyskinesia, such that
high levels of cAMP during early development decreases neuronal cell-type production,
as well as exerting its downstream effects on D2 (dopamine 2) receptor and tyrosine
hydroxylase protein expression, thereby disrupting the dopamine pathway. Understanding
the pathophysiological mechanisms underlying this disease will help differentiate
ADCY5 related-dyskinesia from other motor disorders, in order for clinicians to make
informed decisions about treatment. Future steps will include the use of patient iPSCs to
iii

individually diagnose mutation type, quantify cAMP production level, and customize
drug treatment.
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INTRODUCTION

ADCY5-related dyskinesia is a rare genetic neurological movement disorder, with
early onset in childhood (Mencacci et al. 2015). Although this disease is not fatal and
does not progress with age (Fernandez et al. 2001), the effects are challenging and
debilitating for patients and their families. The disease phenotype was first described in
2001, when Dr. Magali Fernandez and colleagues performed a study on 18 related
individuals (spanning over five generations) diagnosed with “some variation” of benign
hereditary chorea (BHC). Case workup, including family history, revealed that patients
did not continue to deteriorate as in Huntington’s disease, and in some cases, there
seemed to be improvement with age. Patients’ conditions seemed to be worsened by
anxiety and stress. There were no marked abnormalities in blood chemistries reported,
cognitive dysfunction, or shortened life span; MRI’s were normal, deep tendon reflexes
were normal, and muscle strength and tone were all normal. Needle electromyogram
(EMG) recordings were used to measure patients’ facial muscle electrical activity which
displayed myokymic electrical discharges. The disease was re-named to Familial
dyskinesia with Facial Myokymia (FDFM) due to the various dyskinesias and myokymic
presentation. FDFM differs from BHC in the way it clinically presents, such that BHC
often presents with pulmonary and or endocrine defects and FDFM does not. Also,
BHC’s predominant symptom is chorea, and although FDFM does manifest with the
neurological-related chorea, it also presents with other multiple abnormal movements,
including facial myokymia, dystonia, hypotonia, myoclonus, dysarthria, paroxysmal
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episodes, as well as delayed developmental milestones, with early onset in childhood to
adolescence (Fernandez et al. 2001).
In order to analyze the genetic basis of this disease, Fernandez et al. 2001
examined the family pedigree of the five-generation family study and discovered the
mode of inheritance to be autosomal dominant, with complete penetrance in males and
females; and some cases revealed male to male transmission. The authors proposed that
the gene mutation responsible for FDFM was most likely related to an ion channel due to
some patients’ positive response to propranolol, a beta-adrenergic antagonist, as well as
acetazolamide, an inhibitor of carbonic anhydrase. They performed linkage analysis on
fourteen genomic regions containing genes that code for portions of ligand-gated ion
channels in addition to genes associated with myokymia or chorea, but it was not
informative (LOD score of 2.7, below the significance level of 3.0). A haplotype analysis
was constructed from haplotypes of living affected family members. They found that
many affected individuals did not share the haplotype with their affected siblings, or even
affected relative. They also demonstrated that FDFM is not an allelic variant of any of the
candidate genes examined.
The first exome sequencing of a FDFM affected individual was performed in
2012 by Che, et al. The disorder was mapped to a region on chromosome 3 that contained
a missense mutation in the coding sequence for Adenylate Cyclase 5 (ADCY5). Since
this discovery, a total of 89 patients presenting with symptoms of FDFM have tested
positive for a mutation in the ADCY5 gene (Table 1). These individuals include related
family members, as well as non-related sporadic cases, and includes an array of genotype
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to phenotype relationship. (Chen, et al. 2012; Chen, et al. 2014; Carapito et al. 2015;
Chen, et al. 2015; Douglas et al. 2017; Dy et al. 2015; Menacci et al. 2015; Chang et al.
2016). According to my most current literature search, there are 17 identified ADCY5
point mutations associated with diseased individuals (Douglas et al 2017), as well as one
amino acid deletion mutation, for a total of 18 identified ADCY5 mutations associated
with the disease (Table 1). The p.R418W mutation in ADCY5 is carried by the majority
of ADCY5 patients examined to date and is associated with the more severe phenotypes
(Chen, D. et al. 2015; Zech et al. 2017 ).
The ADCY5 gene is 173,250 bp long and contains 21 exons located on the q arm
of chromosome 3 (reviewed in Shaw 2015). The coding sequence is 3,786 bp long,
encoding 1,262 amino acids (National Center for Biotechnology Information [updated
2018]). ADCY5 has two identified splice variants that contain the first half of the
molecule identified by BLAST analysis against EST databases. The first ADCY5 variant
ends at domain C1a, and the second variant ends at the beginning of C2. This has been
found similar to the truncated ADCY5 molecule found in cDNA libraries made from
canine ventricular tissue. Though inactive on their own, it is hypothesized that the
truncated isoforms may allow for heterodimerization in vivo (Katsushika et al. 1992).
ADCY5 is one of the 9 transmembrane human adenylate cyclase proteins
expressed from the adenylate cyclase genes conserved in all mammals. There is also a
10th ADCY protein that is soluble, structurally different from the others and is testis
specific (Chen et al. 2012; reviewed in Dessauer et al. 2017). ADCY5 encodes for a
plasma membrane-bound glycoprotein that is an effector enzyme of G-protein coupled

Deleted:

4
receptors (GPCRs). (Ludwig and Seuwen 2002). The ADCY 5 protein is grouped into
adenylate cyclase category III (reviewed in Dessauer et al. 2017), which is defined due to
inhibition by Ca2+, PKA, and Gαi subunit and activation by forskolin, isoproterenol,
PKC, Gαs & Gβγ subunits, and Mn2+ (reviewed in Hurley 1999).
The enzymatic role of adenylate cyclase is the conversion of adenosine
triphosphate (ATP) to cyclic adenosine-3’,5’- monophosphate and pyrophosphate. Once
cAMP is synthesized, it serves as a second messenger within the cell. Cyclic AMP’s most
prominent role is to phosphorylate cAMP-dependent protein kinase (PKA), which in turn
can phosphorylate other molecules causing a wide array of downstream signaling cascade
effects, including inhibition of ADCY5 in circuit (Dunman and Nestler 1999). A common
role for PKA is the phosphorylation of the transcription factor cAMP response element
binding protein (CREB). Phosphoactive CREB translocates to the nucleus where it binds
the DNA sequence known as cAMP response element (CRE) to regulate the expression
of a variety of genes that include some involved in neural cell function such as BDNF,
NGF, and PACAP (Dworkin et al. 2009).
The transmembrane ADCY proteins have two transmembrane domains (TM1 and
TM2), each comprised of 6 transmembrane helices each and two cytosolic catalytic
domains (C1 and C2). The two catalytic domains have an “a” and “b” subunit. C1 is
connected to TM1 and C2 is connected to TM2. Residues of both C1a and C2 come
together in a heterodimer to form the active site at one end of the ventral groove
(Willoughby and Cooper 2007). The active site of this enzyme is lined with hydrophobic
residues allowing for hydrophobic interactions to cradle the purine ring of ATP. The
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arginine residue of C1 and the lysine residue of C2 form the charged interactions of the
catalytic domain. The C1 domain helps to correctly orient the lysine residue in C2, which
in turn is necessary for the flexibility of the active site. Any mutation that changes the
specific amino acid residues located within this catalytic site may affect the specificity by
preventing proper interaction between C1 and C2 (reviewed in Hurley 1999).
In humans, ADCY5 is predominantly expressed in the striatum (Matsuoka et al.
1997; Kim et al. 2006; Menacci et al. 2013). The dorsal striatum includes the caudate
nucleus and putamen, and the ventral striatum includes the nucleus accumbens olfactory
tubercles (Figure 1), both dorsal and ventral subsections make up the basal ganglia,
subcortical structures involved in movement, learning, and memory (reviewed in Money
and Stanwood 2018). In particular, the nigrostriatal pathway of the basal ganglia has a
role in controlling voluntary muscle movement. A study demonstrated that ADCY5
mRNA expression continues to increase in the human striatum during early development,
from 50 to 500 days post conception, when compared to other regions such as
hippocampus, frontal cortex, or medulla oblongata (Menacci et al. 2015). This indicates
that the level of ADCY5 expression is associated with early development, in a temporalspatial manner.
A study by Matsuoka et al 1997 used neonatal and adult rat brain to research
mRNA expression of ADCY1, 2, and 5. They found ADCY5 was restricted to striatum,
nucleus accumbens, and olfactory tubercle. There was low ADCY5 mRNA expression in
these regions in the neonatal rat brain, then a significant increase in these same regions
after postnatal day(?) 7. Expression of ADCY5 mRNA is also associated with the
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maturation of striatal neurons, while ADCY2 is more distributed throughout the adult rat
brain and ADCY1 is abundant in the dentate gyrus of the adult rat brain. The results of
their entire study show that ADCY protein 1, 2, and 5 expression is brain region specific,
as well as age specific, which they concluded that these specific proteins may have a role,
“not only in the synaptic transmission, but also in the differentiation and maturation of
neuronal cells in the developing brain” (Matsuoka et al. 1997).
ADCY5 expression has also been characterized in other human tissues. In 2002,
Ludwig and Seuwen performed a study in which ADCY expression profiles were created
using 16 different tissues from human as well as HEK 293T cells. Using RT-PCR, they
found ADCY5 expressed in 14 of the 16 different tissue types, with highest expression in
heart, brain, and testes. In HEK 293T cells, cDNA expression of most adenylate cyclase
proteins was found, except 4, and 8; and 2 was faintly detectable. A band of moderate
intensity for ADCY5 was detected at 300bp (as reviewed in Ludwig and Seuwen 2002).
Later, expression of ADCY proteins 1, 3, 4, 5, 6, 7, and 9 was confirmed in HEK 293T
cells (Atwood et al. 2011).
Interestingly, all the mutations identified in ADCY5 patients occur within the
catalytic domains of the protein (Chen, et al 2015; Chang et al. 2016; Douglas et al. 2017;
Dy et al 2016).) (Figure 2). To determine how these mutations might affect biochemical
function, a significant study performed in 2014 by Ying-Zhang Chen and colleagues at
the University of Washington concluded that the FDFM phenotype may be due to a gainof function effect due to a mutation found in the adenylate cyclase 5 gene. HEK 293T
cells were transiently transfected with either an empty GFP expression vector, GFP
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vector + wild-type ADCY5, or GFP vector encoding two mutations identified in ADCY5
patients: p.R418W, or p.A726T. They then measured subsequent cAMP production in the
basal state and under pharmacological regulation by the ADCY class III beta adrenergic
agonists forskolin and isoproterenol, and the ADCY antagonist, propranolol. ADCY5
protein levels were not affected by the mutations; however, cAMP levels in mutated
ADCY5 were significantly higher than basal levels but only when stimulated by
pharmacologics, demonstrating a gain-of-function effect. This suggested increased cAMP
could be related to disease phenotype in patients carrying these mutations. (Chen, YZ. et
al. 2014). They performed whole exome sequencing on affected individuals and
discovered several missense variants within the ADCY5 gene. Of note, one of those
variants, includes (c.1252C>T, p.R418W), which is of interest for our study. They also
mapped these mutations to the catalytic domains of ADCY5.
To date, there is not a solid understanding of the molecular mechanisms by which
ADCY5 mutations result in the disease phenotypes. However, there is evidence in the
literature to suggest that neuronal differentiation might be affected. Production of cAMP
by ADCY5 affects axon elongation, through the P13-Akt-GSK3 pathway. (Puerto, et al.
2012). Specifically, the three purinergic receptors P2X7, P2Y1, P2Y13, widely expressed
in neurons and glial cells of the adult brain, contribute to the regulation of ADCY5. The
metabotropic receptor P2Y1, promotes axonal elongation through activating cAMP
production in the distal region of axons of hippocampal neurons, exerting its effects on
downstream effectors that include neurotrophic factors. The P2X7 and P2Y1 receptors
halt axonal elongation by inhibiting cAMP synthesis(?) through induction of Ca2+ influx
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(Puerto et al. 2012). An extensive study by Dworkin et al. 2009 found that the
downstream cAMP target, CREB, has an essential role in neurogenesis of the developing
mouse brain, where it is found to be constitutively active during neural progenitor cell
differentiation, and only “transiently activated outside the neurogenic regions” (Dworkin
et. al. 2009).
Because axonal elongation and neuronal connectivity are so dynamic during
development, it is important to consider the dysregulating influence that mutated ADCY5
might contribute during embryonic stem cell differentiation to a neuronal lineage, and
specific to dopamine-containing neurons (which are involved in motor control) that are
often implicated in other motor disorders such as Parkinson's disease (reviewed in Girault
JA, and Greengard 2004; reviewed in Money and Stanwood 2013). ADCY5 knockout
mice develop a movement disorder, displaying Parkinsonian-like movements.
Interestingly, their symptoms were worsened by stress (Chen YZ 2012); and stress is a
known exacerbator of patients with ADCY5-related dyskinesia (Fernandez et al. 2001;
Chen DH et al 2015; Dy et al. 2016). Looking at the biochemical regulation of ADCY5,
it is also known that adenylate cyclase activity is “modulated through dopamine
signaling” (reviewed in Girault JA, and Greengard 2004). Dopamine receptors, with
excitatory (D1) and inhibitory (D2) subclasses, are responsible for modulating the ion
channel permeability upon dopamine binding, thereby influencing the neuronal
membrane potential (Girault, and Greengard 2004). These changes in membrane potential
may then in turn affect neuron action potentials. Abnormal firing of motor neurons has
been proposed by Chen YZ et al. 2012 as a possible explanation for the myokymia seen
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in such motor diseases. D1 and D2 are G-protein-coupled receptors that activate and
inhibit ADCY5, respectively (Chen DH et al 2015; Puerto et al. 2012; Iwamoto et al.
2003). Both D1 and D2 are abundant in the striatal regions of the brain, regions that are
responsible for movement and motor learning (Chen YZ, et al 2012; reviewed in Money
and Stanwood 2013)
Of relevance, dopamine-containing neuronal innervation, as well as dopamine
receptor expression is dynamic during early development and continues long after birth.
It has been suggested that “This prolonged developmental timeline provides a large
window of critical periods during which potential disruptors can induce varied effects”
(reviewed in Money and Stanwood 2013). Because the striatum (enriched with ADCY5),
receives innervation from dopamine-containing neurons, any disruptors of this pathway
could be proposed as problematic. In fact, this may be responsible for the broad-spectrum
of clinical presentation (Chen DH et al. 2015) that we see with ADCY5-related
dyskinesia.

Research Aims

It remains unclear how mutations in ADCY5 contribute to the disease phenotypes
of ADCY5-related dyskinesia at the cellular level. Evidence suggests that mutant forms
of ADCY5 result in increased intracellular levels of cAMP in HEK cells. However, it is
not known if the ADCY5 disease phenotypes are a result of changes in cAMP

10
production, or degradation, and if these changes affect development, cellular function, or
both. If increased levels of cAMP in these mutations do affect neuronal differentiation,
this would create changes in development and/or the connectivity of neurons and may
account for the differences we see in phenotypes amongst patients with the same
mutation. This study sought to address the question of whether cAMP concentration
affects the differentiation of dopamine-containing neurons and if endogenous cAMP
levels are affected by endogenous expression of the most common mutation seen in
patients with ADCY5-associated dyskinesia, p.R418W. To address these questions, the
following aims were proposed:
1. Determine if db-cAMP levels affect differentiation of mouse embryonic stem
cells into dopaminergic neurons. It is unknown if the effects of the ADCY5
mutations on disease phenotype results from changes in development, cellular
function, or both. To better explore this question, mouse embryonic stem cells were
treated with a synthetic, membrane permeable form of cAMP, N6,2'-Odibutyryladenosine 3':5'-cyclic monophosphate sodium (db-cAMP) at a range of
concentrations (0, 350 µM, 700 µM, 1400 µM or 2800 µM), to see if cAMP affects
differentiation to dopaminergic neurons.

2. Creation of a CRISPR-induced ADCY5 point mutation, c.1252C>T, in HEK
293T cells. Although overexpression of ADCY5-GFP fusion protein, containing the
mutation, p.R418W, increases cAMP production in 293T cells, when
pharmacologically activated using beta-adrenergic agonists (Chen YZ et al.2014), it
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is not clear if cAMP production is affected when ACDY5 is pharmacologically
activated in cells that express the mutation from the endogenous loci. To test this, we
created the c.1252C>T (p.R418W) mutation in HEK 293T cells using the
CRISPR/Cas9 genome editing system. The mutation was made by first designing the
sgRNA to target the specific sequence of exon 2 in the ADCY5 gene that contains
the variant nucleotide of interest. Cas9 made the cut just 5’ upstream to the
protospacer adjacent motif (PAM) sequence. This point mutation was repaired with
the desired nucleotide (thymine) by providing the cells with a single-stranded
template oligo of 150 bp long. The mutation was confirmed by PCR amplifications,
followed by sequencing. The initial goal was to stimulate cAMP production in these
endogenously mutated cells by pharmacological regulation with the agonist,
isoproterenol, then quantify the amount of cAMP produced, using an enzyme-linked
immunosorbent assay (ELISA). However, because other non-silent mutations were
also created directly upstream and downstream the variant nucleotide, ELISA was
not performed. Optimization of the CRISPR-induced mutation to reduce or eliminate
off-target effects is pre-requisite to performing ELISA, so that in the future, these
genomic editing tools would be useful to the scientists working with the patient
family cell lines through our collaboration with Rare Science.
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MATERIALS AND METHODS

Neuronal Differentiation of Mouse Embryonic Stem Cells

J1 murine embryonic stem cell culture
Mouse embryonic cell, J1 cell line, derived from a 129S4/SvJae male blastocyst
(ATCC® Cat# SCRC1010) (American Type Culture Collection (ATCC®), Manassas,
VA). mESCs were plated on a MEF layer of 30,000 cells/cm of mitomycin C treated p2
2

mouse embryonic fibroblasts (MEFs, CytoSpring LLC, Mountain View, CA) at 30,000
cells/cm in culture dishes pre-treated with 0.1% gelatin solution (STEMCELL
2

Technologies™ Inc, Vancouver, BC, Canada or EMD Millipore, Temecula, CA). Cells
were maintained at 37° C in 5% CO2 in mESC culture media (1% of 2.0 mM L-alanyl-Lglutamine (STEMCELL Technologies™ Inc, Vancouver, BC, Canada), 1% of 1x
nonessential amino acids (STEMCELL Technologies™ Inc, Vancouver, BC, Canada),
0.1% of 1000x 2-mercaptoethanol (Sigma- Aldrich®, Louis, MO), 0.1% of ESGRO®
Mouse Leukemia Inhibitory Factor (LIF) (EMD Millipore, Temecula, CA), 15% of fetal
bovine serum and 82.8% of DMEM (Life Technologies, Grand Island, NY and ATCC®,
Manassas, VA). Approximately 72 hours post initial culturing, mESCs were passaged at
50% confluency to remaining MEF wells.
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EB formation
mESCs were harvested at 50% confluency and plated on 0.1% gelatin-coated TC
dishes for 48 hours. The mESCs were harvested with 0.05% trypsin EDTA and plated in
suspension culture at 500,000 cells/well in a 6-well ultra-low adherent dish (SigmaAldrich®, Louis, MO) in 3 mls of differentiation media (15% of ES-Cult ™ fetal bovine
serum (STEMCELL Technologies™ Inc,Vancouver, BC, Canada), 10 mM of MEM
Non- Essential Amino acids, 2 mM of L-glutamine (Life Technologies, Grand Island,
NY), 1 mM of 1-thioglycerol (Sigma- Aldrich®, Louis, MO ) and DMEM media (Life
Technologies Life Technologies, Grand Island, NY and American Type Culture
Collection, Manassas, VA). Cells were incubated for 4 days. Media was changed every
other day by transferring the media and EB’s from each well to a sterile 15 ml conical
tube, allowing settling to the bottom of the conical tube for 5 minutes. Spent media was
removed and replenished with 3 ml of new differentiation media.

Nestin enrichment
EBs were transferred to 6-well tissue culture plates and incubated for 7 days.
Cells were fed every other day with ITSFn media prepared in-lab: 1X DMEM-F12
(Gibco™ Life Technologies, Grand Island, NY), 5 µg/ml insulin (Sigma-Aldrich®, St.
Louis, MO ), 50 µg/ml apotransferrin (Athens Research, Athens, GA), 30 nM sodium
selenite (Alfa Aesar, Haverville, MA), 250 ng/ml fibronectin (Sigma-Aldrich®, St.
Louis, MO), 2.5 mM L-alanyl-L-glutamine (Gibco™ Life Technologies, Grand Island,
NY).
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Expansion of nestin positive cells
On day 7 of enrichment, cells were harvested, triturated into a single-cell
suspension, and plated on sterile coverslips at 75,000 cells/cm for all treatments and
2

replicates. Sterile coverslips were prepared by incubating in 15 µg/ml of poly-L ornithine
(Sigma- Aldrich®, Louis, MO) for 30 minutes at room temperature, rinsing 3 times in
sterile PBS, followed by incubation in 1 µg/ml laminin (STEMCELL Technologies™
Inc, Vancouver, BC, Canada) for 3-5 hours at 37° C. The cells were expanded for 4 days
of incubation, feeding every other day in N3 media (ITSFn media plus 20 nM
progesterone, 100 nM putrescine (all from Sigma-Aldrich®, St. Louis, MO), and 1 µg/ml
laminin (STEMCELL Technologies™ Inc., Vancouver, BC, Canada or EMD Millipore,
Temecula, CA), 500 ng/ml Shh, 10 ng/ml bFGF, and 100 ng/ml FGF8b (all from
STEMCELL Technologies™ Inc, Vancouver, BC, Canada or EMD Millipore, Temecula,
CA).
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Dopamine-containing neuronal differentiation
Dopaminergic differentiation was initiated by the removal of cytokine bFGF from
N3 media and the addition of 200 µM ascorbic acid. Cells were fed every other day for
10 days, and pre-designated wells were treated on feeding days with 0 µM, 700 µM, 1400
µM, or 2800 µM db-cAMP, N6,2'-O-dibutyryladenosine 3':5'-cyclic monophosphate
sodium (CAS# 60-92-4) (Sigma- Aldrich®, Louis, MO).

Immunocytochemistry
On the tenth day of dopaminergic differentiation, cells on coverslips were fixed
with 4% paraformaldehyde in PBS for 20 minutes at 4° C. Paraformaldehyde was
discarded, and cells were washed twice with PBS. The cells were then treat with 70%
ETOH at room temperature for 5 minutes, rinsed once with rinsing buffer (0.25%
Triton™-X-100 (Sigma- Aldrich®, Louis, MO) in PBS, and treated with blocking
buffer blocking buffer (2% goat serum (Thermo Fisher Scientific, Waltham, MA) in
0.25 %Triton™-X-100 (Sigma- Aldrich®, Louis, MO) in PBS) for 30 minutes at room
temperature . After blocking, cells were incubated with primary antibody, mouse- antibeta-tubulin III (Cat # MAB1195, Lot # HGQ011611) (R&D Systems, Minneapolis, MN)
for one hour at room temperature, followed by four washes with rinsing buffer for 5
minutes each. Goat anti-mouse secondary antibody-Texas Red™ (Ref # T862, Lot #
1880649) (Invitrogen™, by Thermo Fisher Scientific, Waltham, MA) was added for one
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hour at room temperature in dark conditions, followed by three washes with rinsing
buffer. All antibodies were diluted in working buffer (1% BSA, 0.1% Triton-X in PBS).
After the secondary antibody incubation and rinses, cells were incubated in blocking
buffer for 30 minutes at room temperature. Blocking buffer was removed and the
additional primary antibody was added: mouse-anti-TH (Cat# AB152, Lot 2861858)
(R&D Systems, Minneapolis, MN), and incubated for 1 hour at room temperature.
Coverslips were then rinsed four times in rinsing buffer with 5 minutes for each wash.
The additional secondary antibody was added: goat anti-mouse Alexa-Fluor™ Plus 488
(Ref# A3273, Lot # SE250296) (Invitrogen™, by Thermo Fisher Scientific, Waltham,
MA) and incubated for 1 hour at room temperature, then rinsed three times with rinsing
buffer, 5 minutes each wash. Stained cells were mounted on glass slides with 10 µl of
ProLong® Gold antifade reagents with DAPI (Life Technologies, Grand Island, NY), and
left to dry at room temperature overnight.
Images were taken using a Zeiss Axio Observer Z1 Fluorescent Microscope at
200X total magnification using 350 nm excitation and 450 nm emission filters to
visualize DAPI, 595 nm excitation and 615 nm emission filters to visualize Texas Red
and 490 nm excitation and 520 nm emission filter was used for the visualization of green
fluorescence.
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Neuronal cell quantification
ZEN 2.3 software modules for image analysis and colocalization (Carl Zeiss Inc,
Thornwood, NY) were used to quantify total cell number, Tuj1 and TH positive cells.
Four field of view images were taken per replicate of each treatment and the total number
of cells were summated. The total numbers per replicate were then averaged to generate
the average number of cells of per treatment. Both Tuj 1 and TH positive cells were then
divided by the total cell population, represented by the average DAPI nuclei count. Tuj 1
and TH positive cell percentages out of total cell population were then used to perform a
one-way ANOVA. In addition, TH positive cells were also divided by the number of
Tuj1 positive cells to get the percent dopaminergic neuron type out of total number of
neurons.
CRISPR Cas9 HEK 293T Genome Editing

HEK 293T cell culture
HEK 293T cells (Lenti-XTM) (Clontech, Mountain View, CA) were cultured in
90% Dulbecco's Modified Eagle Medium (DMEM, Life Technologies, Grand Island,
NY) and 10% fetal bovine serum (Life Technologies, Grand Island, NY) and incubated at
37°C in 5% CO2. HEK 293T cells were plated in 2 ml of fresh growth media/well, at a
density of 30,000 cells/cm . Cell number and viability were assessed using trypan blue
2

assay, in a 1:10 dilution with a 0.4% Trypan Blue solution (Life Technologies, Grand
Island, NY). Cells were counted, using 10 µl of cells in Trypan Blue, loaded on both
sides of a hemocytometer, then visualized by inverted microscope, at 100X total
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magnification. Cells were then passaged at 30,000 cells/cm . Media was replenished
2

when the media color was orange or yellow, indicating increased acidity, from depletion
of nutrients, and buildup of H protons. The cells were subcultured when they reached
90 % confluency.

ADCY5 genomic primer design
Forward and reverse primers targeting ADCY5, exon II were designed by web
tool, Primer-BLAST (Ye et al. 2012. accession # NG_033882.1), to amplify a 441 bp
region that includes the variant nucleotide of interest. Primers flank all of exon 2, that
includes the variant nucleotide. (Figure 3). ADCY5 Primers (Integrated DNA
Technologies, Skokie, IL) were tested on genomic DNA extracted from HEK 293T
cells. Primer sequences are as follows:
Forward: 5- AGGACATCAGAGAGCCCGAT -3’
Reverse: 5’- GCTGGCAGCCGTAATAAGC -3.

sgRNA and repair template design
CRISPR protocol (Addgene, Cambridge, MA) (www.addgene.org/crispr/zhang)
was followed for editing of the 441 bp region of interest. Both single guide RNA’s
(sgRNA) design were completed by entering desired sequence of exon 2 of human
ADCY5 (Accession # NG_033882.1) into www.crispir.mit.edu web tool to generate
guide options with various scores of off targeting effects. Higher scores are inversely
proportional to off targeting effects. The chosen sgRNAs were as follows:
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(5’-GGAGACCTCAGCCGGATAGT GGG-3’ with score of 93 out of 100) (“original”
sgRNA); and later, for a dual nickase approach, a second sgRNA was added: 5’CACCGCCCGAGAGTGCATCCAGGCG-3’, score of 94). The sgRNA-Cas9 vector
construct was used to target the sequence in ADCY5 exon 2 that contains the variant
nucleotide, as well as the 5’ protospacer adjacent motif (PAM) sequence, within the
correct reading frame. A single-stranded 150 bp repair template (Integrated DNA
Technologies, Skokie, IL), that spanned between the Cas9 cut site and the variant
nucleotide, was created for homology directed repair, in order to obtain the missense
mutation c.1257C>T, as well as a silent mutation in the PAM sequence from CCC to
CAC, in order to prevent Cas9 from repetitious cutting after editing.
Px459 Bpil digest
Digestion of the initial Px459 (PsPCas9(BB)-2A-Puro (PX459) V2.0 vector, and
later the PX462 (PsPCas9(BB)-2A-Puro (PX459) V2.0) vector was performed according
to protocol (Addgene, Cambridge, MA) (www.addgene.org/crispr/zhang). Each
digestion included 1 µg of plasmid, 1 µl Fast Digest Bpil (Cat# FD1014) (Thermo
Scientific, Waltham, MA), 1µl Fast AP (Thermo Scientific, Waltham, MA), 2 µl 10X
Fast Digest Buffer (Cat# EF0651) (Thermo Scientific, Waltham, MA), 14.5 µl ddH 0, and
2

incubated for 30 min at 37°C.
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Annealing and phosphorylation of forward and reverse sgRNA oligos
Addgene protocol (Addgene, Cambridge, MA)
(www.addgene.org/crispr/zhang) was followed for annealing, phosphorylation and
ligation of forward and reverse sgRNA oligos. 2 µl of each forward and reverse sgRNA
oligo (100 µM) (Integrated DNA Technologies, Skokie, IL) was combined with 2 µl of
10X T4 Ligation Buffer (Cat# B0202S) (New England Biosciences®, Ipswich, MA), 13
µl ddH 0, and 1 µl T4 Polynucleotide kinase (Cat#M021S) (New England Biosciences®,
2

Ipswich, MA).
Thermal cycle conditions were as follows:
37°C for 30 min,
95°C for 5 minutes
ramp down to 25°C at 5°C/min (0.08° C/sec)

Ligation
The Addgene protocol for ligation was followed (Addgene, Cambridge, MA)
(www.addgene.org/crispr/zhang). After amplification, a working dilution of
annealed/phosphorylated sgRNA oligos was made at 1:200 for ligation. The ligation of
annealed/phosphorylated oligos to vector included: 2 µl of Bpil-digested Px459 plasmid,
1 µl annealed/phosphorylated oligos (1:200), 5µl 2x Quick Ligation Buffer™ (Cat#
B2200S) (New England Biosciences®, Ipswich, MA), 3 µl dH 0, and 1 µl T7 DNA Quick
2

Ligase™ (Cat# M0318S) (New England Biosciences®, Ipswich, MA). The ligation
reaction was incubated at room temperature for 10 min.
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Bacterial transformation
Transformation of the initial plasmid PX459 V2.0, and later PX462 (Addgene,
Cambridge, MA) was performed by combining 2 µl ligation product (Px459 + sgRNA
insert) with 50 µl Max Efficiency DH5α competent cells (Cat # 18258-012)
(Invitrogen™, Thermo Fisher Scientific, Carlsbad, CA), then incubating on ice for 2 min,
heat shock for 45 seconds at 42ºC, and back on ice for 1 minute. SOC media (450 µl) was
added and bacteria were incubated at 37°C for 30 min, shaking at 225 rpm, before plating
100 µl onto pre-warmed LB-ampicillin (50 µg/ml)-Agar plates, then incubated at 37º C,
overnight.

Colony PCR
Confirmation of proper cloning of the insert was confirmed by single colony
PCR. The growth of colonies on LB-ampicillin plates indicated a likely successful
bacterial transformation, as the no-transformation control plates produced no growth, and
the empty-vector transformation control plate had very few colonies, due to background
re-annealing of plasmid. Individual colonies were selected at random from the
transformation plate with a sterile toothpick and swished in individual PCR tubes
containing PCR cocktail. EconoTaq Plus® 2X PCR Master mix (reagent) and EconoTaq
Plus® protocol (Cat # 30035-1) (Lucigen®, Palo Alto, CA) were used, along with
previously designed sgRNA oligo (Integrated DNA Technologies®, Skokie, IL) as the
forward primer and a vector-specific reverse primer (Integrated DNA Technologies®,
Skokie, IL) to target the area of interest, generating an expected amplicon product of 100
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bp, which included our sgRNA. Primers were diluted 1:50 and used in the PCR reaction
with the following thermal cycle conditions:
95°C x 2 min, for initial denaturation
95°C x 30 sec
52.2°C x 1 min
72°C x 30 sec
Repeat 30 cycles
Final extension at 72°C x 5 min
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Mini-culture, plasmid mini-prep, and glycerol stocks
Colonies that produced PCR products of correct amplicon size (100 bp) were
chosen for plasmid mini-prep purification to be used in later transfection. First, those
same colonies were selected again with a sterile toothpick and placed in individual tubes
containing LB-broth ampicillin (50 µg/ml), and grown overnight at 37º C, shaking at 225
rpm, according to protocol (Addgene, Cambridge, MA). Approximately 14 hours later,
half of the broth was used for a plasmid mini-prep, and the other half combined with
equal volume of sterile glycerol and froze at -80ºC for preservation. Plasmid mini-prep
purification was performed according to protocol (Ref # 740499.50) (Macherey-Nagel,
Inc., Bethlehem, PA): Bacterial cell pellets were lysed and clarified before DNA was
bound to spin columns, pellets were washed in buffer supplemented in ethanol, spin
column membranes were dried by centrifugation, and DNA eluted in 50 µl elution buffer.
Plasmid concentration was determined by NanoDrop 1000 spectrophotometer (Thermo
Fisher Scientific, Waltham, MA).
Transfection of HEK 293T cells
Transient transfection of PX459-sgRNA construct into HEK 293T cells was
performed using the Lipofectamine 3000® protocol (Ref L3000-008) (Life Technologies,
Grand Island, NY). Experimental design included 2 replicates of transfected wells, 2
replicates of empty-vector transfected control wells, and 2 wells of non-transfected HEK
cells. Cells were transfected when they reached 90% confluency with 250 ng sgRNAPx459 construct as well as 1 µg of the 150 bp single-stranded repair template for
homology directed repair. For visual confirmation of effective transfection, all cells in all
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wells, except the non-transfection control wells were transfected with 750 ng of the
pMAX vector containing a green fluorescent protein and a puromycin resistance gene
(Cat# D-00069) (Lonza, Basel, Switzerland). GFP expression was confirmed and
documented 24 hours post-transfection with a Zeiss Axio Observer Z1 Fluorescent
Microscope at 200X total magnification. (Carl Zeiss Inc., Thornwood, NY).

Puromycin selection
Upon visual confirmation of transfection efficiency, cells were treated with 2.5
ug/ml puromycin added to the media to allow for sgRNA-Px459-transfected colony
selection. Media was changed daily and puromycin treatment repeated every 24 hrs until
all non-transfected HEK cells were dead (approximately 67 hrs). HEK cells were treated
with 0.05% trypsin to harvest wells individually and transferred to 10 cm plates, plated at
5,000 cells total per plate and cultured until individual colonies were able to be visualized
by microscopy.

Single Clone Selection
Upon colony formation, the individual transfected clones were passaged without
trypsin. Using a P10 micropipette, under a 10X objective, individual clones were
aspirated and transferred to a well of a 96-well tissue culture plate for culture. Each time
cells reached 90-100% confluency, individual clones were successively passaged to 24
well tissue culture plates, then 12-well plates, and finally transferred to 6-well plates
before harvesting individually for genomic DNA extraction. When harvested, half of
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each clone was cryopreserved in freezing media (50% FBS, 40% DMEM, and 10%
DMSO) and the other half pelleted and stored frozen at -20°C, until DNA extraction.

293T cell genomic DNA extraction
Extraction of genomic DNA from transfected HEK293T frozen cell pellets was
performed according to Qiagen DNeasy blood and tissue kit and protocol (Cat # 69504)
(Qiagen, Germantown, MD), and quantified by NanoDrop 1000 spectrophotometer
(Thermo Fisher Scientific, Waltham, MA).

Sequence confirmation of genomic edit
Initial confirmation of CRISPR editing was performed by screening genomic
DNA from sgRNA-transfected HEK clones for correct amplicon size using polymerase
chain reaction (PCR). EconoTaq Plus® 2X PCR Master mix (Cat # 30035-1) (Lucigen®,
Palo Alto, CA) was used, with previously designed ADCY5 primers to confirm band
size, as well as single amplified product present per transfected clone. A non-transfected
genomic DNA sample was used as a positive control. Clones producing a single correct
amplicon product size (~440bp), were sent out for sequencing (Sequetech, Mountain
View, CA). Forward and reverse genomic ADCY5 primers previously designed and
confirmed to target the locus of interest were used:
Forward: 5- AGGACATCAGAGAGCCCGAT -3’
Reverse: 5’- GCTGGCAGCCGTAATAAGC -3.
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Sequence chromatograms were then analyzed by Snapgene Viewer 4.2 software
(Chicago, IL).

Statistical Analysis

Statistical tests were performed using R statistical software 2013. A one-way
ANOVA was used to analyze all data, and Tukey’s Pairwise comparison was used to
determine significance between groups. The data was described as the mean +/- the SEM.
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TABLES

Table 1: ADCY5 mutations associated with ADCY5-related dyskinesia, including protein
domain, and case documentation (adapted from Douglas et al. 2017). Mosaic cases within
families listed.

Study

New cases

# of cases genotyped,
out of (total affected)

ADCY5
Mutation

Protein
Domain

Chen YZ et al.
2012

1 Family

10(19)

c.2176G>A

C1b

Chen YZ et al.
2014

2 Sporadic (1
mosaic)

2

c.1252C>T

C1a

Carapito et al.
2015

1 Family

2

c.2088 + 1G>A C1b

Menacci et al.
2015

1 Family (1
mosaic),
1 Sporadic

3

c.1252C>T

C1a
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Study

New cases

# of cases genotyped,
out of (total affected)

ADCY5
Mutation

Protein
Domain

Chen DH et al.
2015

1 Family (1
mosaic)
8 Sporadic (3
mosaic)
3 Sporadic (1
mosaic)
1 Sporadic
1 Sporadic
1 Family (1
mosaic)
1 Family (1
mosaic)

16

c.1252C>T

C1a

3
1
1
6(12)
4

c.1253G>A

C1a

c.2176G>A
c.3086T>A

C1b
C2a

2 Families
2 Sporadic
1 Family
1 Sporadic

6

c.1252C>T

C1a

3
1

c.1252C>G
c.1253G>A

C1a
C1a

1 Sporadic
1 Sporadic

1
1

c.2080_2088del C1b
c.1252G>T
C1a

Zech et al. 2016 1 Family
1 Sporadic
1 Sporadic
1 Sporadic
1 Sporadic

2
1
1
1
1

c.2180G>A
c.1378A>T
c.1196C>T
c.1400A>G
c.3625A>G

Chang et al.
2016

Dy et al. 2016

C1b
C1a
C1a
C1a
C2b
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Study

New cases

# of cases genotyped,
out of (total affected)

ADCY5
Mutation

Protein
Domain

Meijer et al.
2016

1 Sporadic

1

c.1252C>T

C1a

Westenberger
2017

1 Sporadic
1 Sporadic

1
1

c.3045C>A
c.3074A>T

C2a
C2a

Douglas et al.
2017

1 Family

4(5)

c.3086T>G

C2a

Table 2: Display of DAPI count averages per replicate and overall average, and std. dev.
and std. error within each treatment. Three replicates of each were listed for each treatment
level, except for 2800 µM, which included two replicates, due to loss of third.

Replicate No treatment 700 µM 1400 µM 2800 µM
1

3603

2352

6689

6649

2

4026

5122

6368

6504

3

2939

4758

6756

Average

3522.66 4077.33

6604.33

6576.50

Std dev

547.93 1505.22

207.39

102.53

Std error

316.35

119.73

72.50

869.04
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Table 3: Statistics for average percent Tuj1 neurons/total cell population (DAPI). Std. dev
and Std. error of percent Tuj1 positive cells within each treatment displayed.
Treatment
Ave # Tuj1
Ave # DAPI Tuj1 ÷ DAPI
Standard
(TX)
No Tx

Standard

X 100%

Deviation

Error

398

3,524.33

11.38 %

4.60

1.32

700 µM

499.66

4077.33

14.02 %

6.64

1.91

1400 µM

622.33

6604.33

9.80 %

3.06

0.88

2800 µM

468

6576.50

7.45 %

3.30

1.16

Table 4: One-way ANOVA statistical output. Statistical output of one-way ANOVA of percent
Tuj1 neurons/total cell population (DAPI), gives a P-value (<0.05), indicating there is a
*significant difference in mean percent Tuj1 positive cells amongst treatment levels.
DF
Sum Sq
Mean Sq.
F-Value
P-Value
Treatment

3

228.9

76.31

3.393

0.027*

Table 5: Tukey’s pairwise comparison for 95% confidence interval for percent Tuj1 neurons/total
cell population (DAPI) , displays the 700 µM treatment-2800 µM pair are the most significantly
different: adjusted p-value (0.02) indicates a significant difference between the mean of 700 µM
and 2800 µM treatment levels.
diff
lwr
upr
P.adj
Pair
700-2800 µM
6.5661
0.7641
12.3680
0.0211*
22.48
Residuals
40
899.6

Formatted Table
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Table 6: db-cAMP treatment does not affect percent TH positive cells out of total cell
population (DAPI). The average TH positive cells divided by total cell population (DAPI). Std.
dev, and Std. error within each treatment level displayed.

Treatment Ave # TH

Ave #
DAPI

TH ÷DAPI x
100%

Standard
Deviation

Standard
Error

No TX

124

3,524.33

3.51 %

1.76854961

0.510536297

700 µM

191

4077.3333

5.43 %

3.520809237

1.01637008

1400 µM

228.33333

6604.3333

3.58 %

1.399712453

0.404062181

2800 µM

181

6576.5

2.89 %

1.190447928

0.420886901

Table 7: One-way ANOVA statistical output. P-value for percent TH positive cells out of total
cell population (DAPI) is not significant (>0.05).
DF

Sum Sq.

Mean Sq.

F-value

P-value

Treatment

3

39.43

13.142

2.599

0.0655

Residuals

40

202.23

5.056

Table 8: db-cAMP treatment does not affect percent TH positive cells out of total number
of neurons (Tuj1). TH positive cells/Tuj1 positive cells. Std. error within treatment levels
calculated.
No Tx

700 µM

1400 µM

2800 µM

% TH 31.15 ± 0.02 38.22±0.04 36.68±0.01 38.9±0.01
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Table 9: One-way ANOVA statistical output. P-value not significant (>0.05).

Treatment
Residuals

Df
3
40

Sum
374.3
2367.0

Mean sq
124.78
59.17

F-value
2.109

P-value
0.114
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Table 10: Summary of CRISPR-induced point mutation attempts. Each CRISPR
attempt listed, including what sgRNA and vector used, and edits made to PAM sequence,
and variant nucleotide.
Attempt

1

sgRNA

original

Vector Correct
PAM edit
made?

Variant nucleotide
edited?

Off target
effects?

Px459

2/3 had
different
edit made.

No.3/3 sequences
with ambiguous
base-calling, with
one detectable wildtype

Ambiguous base
calling after
Cas9 cut site.

Yes. 6 /10

10/10 wild-type

Minimal
ambiguous
base-calling.

5/6 wild-type

Point mutations
and large
INDELS

2

original

3

Original + Px462
X2
Second
Dual
Nickase

1/6

original

No

4

Px459

No.

Px459

1 G>T edit on
reverse strand

2/37 with correct
edit, some wild-type,
and other edit types

Point mutations
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Table 11: Fold-change values (normalized to GAPDH by densitometry) of TH and D2R in
1400 µM cAMP-treated neurons comparing to neurons with no cAMP.

Sample Name

Fold-change to no treatment

Cytosolic TH

1.15

Membrane TH -2.51
Cytosolic D2

1.73

Membrane D2

2.06
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FIGURES

Figure 1: Schematic of the protein structure adenylate cyclase transmembrane proteins.
The mutations identified in individuals with ADCY5 are annotated. Note all mutations are located
in catalytic domains C1 and C2. (Douglas et al. 2017).

36

Figure 2: Schematic drawing of a midsagittal cross section of the human brain. Display of
the medial location of the striatum, and the nigrostriatal pathway (dopaminergic motor pathway),
in relation to the meso-cortico-limbic pathway (Brunelin et al. 2013). From the schematic, we see
the dopaminergic motor pathway projects from the substantia nigra, up to the striatum.

Figure 3: The entire exon 2 sequence of human ADCY5 (NG_033882.1). The intron (not
highlighted) and exon (grey-highlighted) genomic sequences are displayed. The forward genomic
primer is underlined, and reverse genomic primer is in bold print; primers were used to target the
genomic region that contains the variant.
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Figure 4: db-cAMP treatment affects dopaminergic differentiation of murine embryonic stem cells. ICC images
of neurons day 10 of differentiation, displayed per treatment, taken at 200X total magnification. Tuj1: a class
III beta tubulin neuronal cell marker. Tyrosine Hydroxylase (TH): dopaminergic cell marker. DAPI: nuclei staining.
Merge images visually demonstrate an increase in neurons with 700 µM treatment, and then a decrease in overall
neuron count with the higher db-cAMP treatments.
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Figure 5: db-cAMP treatment affects the average number of DAPI. Error bars display mea
n +/- SEM. Average number of DAPI stained nuclei/treatment level was generated by the summa
tion of DAPI count within four field of views, and then averaged by the three replicates/treatment
level. This process was repeated for Tuj1 and TH. The bar graph displays an increasing trend in o
verall cell count for DAPI stained nuclei. One-way ANOVA was significant (P-value=7.05 x10-08
***).
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Figure 6: db-cAMP treatment affects percentage of Tuj 1 and TH out of total cell
population (DAPI). Bar graph of percent average neurons, represented by Tuj1 positive cells,
divided by the total cell population (DAPI) per treatment. Side by side comparison with percent
average TH positive cells divided by the total cell population (DAPI), per treatment. Percent Tuj1
and TH cells display similar trend of dramatic increase with 700 µM treatment, and then a
continual decrease with the higher cAMP treatment. Error bars display mean +/- SEM.
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A).

41
B).

Figure 7: One-Way ANOVA statistical output displays db-cAMP treatment has a
significant effect on percent Tuj1 positive neurons out of the total cell population. A). Box
plots display the interquartile range of percent Tuj1 positive neurons amongst treatment levels,
with the median for each treatment level indicated by the black bar. B). Tukey’s pairwise
comparison graph for 95% confidence interval, displaying the 700 µM treatment-2800 µM pair
are the most significantly different, as the only pair whose confidence interval does not include
zero.
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A).

43
B).

Figure 8: The one-way ANOVA displays db-cAMP treatment does not affect percent TH
positive neurons out of the total cell population (DAPI. TH positive cells divided by the total
cell count (DAPI). A). Box plots display the interquartile range of percent TH positive neurons
amongst treatment levels, with the median for each treatment level indicated by the black bar. B).
Table of TH/DAPI calculations and statistical output of one-way ANOVA, gives a P-value (0.06),
indicating there is a borderline significant difference in mean percent TH positive cells amongst
treatment levels. C). Tukey’s pairwise comparison graph for 95% confidence interval, displaying
the 700 µM treatment-2800 µM pair are the most different, however not considered statistically
significant.
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Figure 9: db-cAMP treatment does not significantly affect the percent TH positive cells out
of total number of neurons (Tuj1 positive cells). Error bars display mean +/- SEM. TH
positive cells divided by total number of neurons (Tuj1), displays a slight increase in percent TH
with 700 µM treatment, then a slight decrease with 1400 µM treatment, followed by a slight
increase with 2800 µM treatment.
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A).

46

B).

Figure 10: The one-way ANOVA displays db-cAMP treatment does not affect percent TH
out of total neurons (Tuj1). A. Box plot of percent TH/Tuj1 displays the interquartile range of
percent TH positive neurons amongst treatment levels, with the median for each treatment level
indicated by the black bar. B. Tukey’s pairwise comparison graph for 95% confidence interval,
displaying the no treatment-2800 µM pair are the most different, however not considered
statistically significant.
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A).

B).
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C).

Figure 11: sgRNA design to target region of variant nucleotide, for CRISPR-induced
c.1252C>T mutation. The entire exon 2 sequence of human ADCY5 (NG_033882.1) (shaded in
light grey) within its genomic DNA region (non-shaded). A). CRISPR attempt #1 and 2: PAM
(shaded dark grey), targeted sgRNA sequence (underlined), and variant nucleotide (capitalized
and bolded). Cas9 will cut just 5’ to the PAM sequence (CCC). B). CRISPR attempt # 3: dual
nickase approach, including both original (underlined), and the second sgRNA (underlined) to
target variant nucleotide (capitalized and bolded). Both PAM sequences highlighted in dark grey.
C). CRISPR attempt # 4: Used only the second sgRNA (underlined), which targets a PAM
sequence (dark grey highlighted) closer to variant nucleotide (capitalized and bolded).
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Figure 12: Successful transfection of sgRNA and GFP into HEK 293T cells, 24 hours posttransfection (CRISPR attempt # 4). A and B. replicates of sgRNA/GFP transfected 293T cells,
displaying GFP expression, indicating good transfection efficiency. C. non-transfected control
displays absence of GFP expression, as expected. D and E. empty-vector transfection controls,
GFP expression indicates good transfection efficiency. F. Non-transfected control replicate
displays absence of GFP as expected. G. Fluorescent image of a sgRNA and GFP-transfected
HEK clone (200X total magnification). H. Brightfield image of sgRNA and GFP-transfected
HEK clones (200X total magnification).
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Figure 13: Treatment with db-cAMP increases D2R’s expression in cytosol and
membrane of 1400 µM-treated neurons; cAMP affects TH’s expression in the cytosol and
membrane of 1400 µM-treated neurons. A). 1400 µM cAMP treated neurons express
approximately 2-fold more D2R in the cytosol and membrane compared to neurons with no
treatment (NT). mESC is negative control; HEK 293T is positive control. Each lane has 10 µg of
protein. B). GAPDH blot for normalizing to D2R. C). cAMP treated neurons express
approximately 1.15-fold more TH in the cytosol and 2.51-fold less in the membrane compared to
neurons with NT. mESCs and HEK 293T are negative control. D). GAPDH blot was used for
normalizing to TH.
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RESULTS

cAMP Treatment Affects Neuronal Differentiation of
Mouse Embryonic Stem Cells

Aim I: determine if cAMP levels affect differentiation of murine embryonic
stem cells into dopamine-containing neurons.
My first aim was designed to determine if cAMP levels affect differentiation of
mouse embryonic stem cells into dopaminergic neurons. My hypothesis was that
increased cAMP during neuronal differentiation would have some effect on either total
cell numbers, number of neuronal cell type, morphology of neurons, or all of the above.
We optimized the dopamine-containing neuronal differentiation protocol published by
Kwon et al. 2014, to achieve efficient directed differentiation of mESCs into dopaminecontaining neurons, confirmed by the presence of Tuj1 and TH, using
immunocytochemistry (ICC)

cAMP treatment affects morphology of neurons
The ICC results demonstrate neuron morphological change with increasing cAMP
treatment (Figure 4). Looking across the treatments, we see a high concentration of
bundle of neuronal processes, which appears to be slightly increased with the 700 µM
treatment. The 1400 µM treatment produces a decrease in the number of neurons present,

52
as well as a change from bundles of neuronal processes, to semi-sparse collection of
neurons, with more prominent somata. We see a dramatic change in morphology in the
2800 µM treated cells, specifically the least dense presentation of neurons, and most
prominent somata.

cAMP treatment affects the overall cell population
Through quantification software post ICC, we were able to confirm cell count
differences amongst db-cAMP treatments and perform statistical analysis on those
results. The number of cells counted/treatment based on DAPI, display an increasing
trend from no treatment to 1400 µM db-cAMP, average cell counts increase, followed by
a decrease in average cells counts with the 2800 µM treatment (Figure 5) (Table 2).

cAMP treatment affects the percent of Tuj1 positive cells in the population
The effect of db-cAMP on the percent of Tuj1 positive cells (representing putative
neurons) out of the total cell population also seems to change with dosage of db-cAMP.
Visualized by ICC, the density of neurons appears to increase with 700 µM treatment
compared to no treatment. There is a marked continual decrease in neuron density from
700 µM to 1400 µM and 2800 µM. This threshold effect suggests that at higher cAMP
treatment, there is a decrease in the overall percentage of cells that differentiate into
neurons. Cell quantification, followed by statistical analysis of the percentage of Tuj1
cells, confirm this interpretation. Box plots display a dramatic increase in the percent of
Tuj1 positive cells from no treatment to 700 µM db-cAMP, then it tapers back down in
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the 1400 µM treatment and even lower in 2800 µM treatment. (Figure 6) (Table 3). For
the percentage of neurons (Tuj1 positive cells) out of the total numbers of cells (DAPI
count), the one-way ANOVA (Table 4) showed there was a significant difference in the
mean percent amongst treatments (P-value<0.05); specifically, the Tukey’s pairwise
comparison (Table 5) shows that the mean percent of Tuj1 positive cells in the 700 µM
treatment is significantly different from the 2800 µM treatment (adjusted P-value=0.021)
(Figure 4). Although visually and quantitatively we see an increase in percent Tuj1 with
the 700 µM treatment vs. no treatment, this is not significantly different from the no
treatment.

db-cAMP treatment does not affect percent TH positive cells out of total cell population
(DAPI)
For the percent of TH positive cells (representing dopamine-containing neurons)
out of the total cell population (DAPI count), we see a similar trend as with percent
Tuj1/DAPI; there is a dramatic increase in the mean percent of TH positive cells from no
treatment to 700 µM, then it tapers down in the 1400 µM and 2800 µM (Table 7).
Because Tuj1/DAPI and TH/DAPI display similar trends, we suspected that cAMP might
not affect TH positive cells specifically, but overall neuronal differentiation efficiency.
To confirm this, the percentage of TH positive cells out of the Tuj1 positive cells were
determined, and results are discussed under the next heading. A one-way ANOVA was
performed (Table 7) on percentage of TH-expressing cells out of the total number of
cells, as indicated by DAPI staining. The ANOVA was not significant (P-value=0.065)
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db-cAMP treatment does not affect the percent of TH positive cells out of total neuronal
cell type
The percent of Tuj1 cells that are also TH positive represent those neurons who
have differentiated to produce dopamine (Table 8). The one-way ANOVA for TH/Tuj1
reveals there is not a significant difference amongst mean percent TH out of total neurons
(Tuj1) (Table 9).

The Creation of the ADCY5 p.R418W Point Mutation

in 293T HEK Cells.

Aim II: characterize the effect of p.R418W mutation on cAMP levels in HEK cells
My second aim sought to characterize the effect of the p.R418W mutation on
cAMP levels in 293T HEK cells. Our hypothesis, based on previous research by Chen et.
al. 2014, predicted that this point mutation produces higher levels of cAMP in mutant
cells, compared to wild-type, when stimulated with the agonists, forskolin and
isoproterenol. To attempt to characterize endogenous expression levels of cAMP in cells
with the p.R418W mutation, a CRISPR sgRNA-plasmid construct was designed to
transfect 293T cells and target the ADCY5 gene, exon II, to create a double stranded
break just 5’ to the PAM sequence, upstream the variant nucleotide c.1252 (Figure 11). A
repair template with the desired mutation was provided during transfection, to use the
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cell’s own homology directed repair mechanism to edit the variant nucleotide to the
desired mutation: c.1252 C>T CRISPR genome editing of HEK 293T cells was attempted
a total number of 4 times, each with a slight modification of the previous attempt (Table
7).

Confirming Transfection Efficiency

To confirm transfection efficiency of our sgRNA-plasmid construct in all
attempts, a GFP-plasmid was also transfected simultaneously, then visualized by
fluorescent microscopy. Each CRISPR attempt produced an average transfection
efficiency of over ~80 percent. In the final attempt, the presence of green fluorescence in
transfected cells about an 80-90 percent transfection efficiency (Figure 12).

Confirmation of CRISPR Edit

The creation of CRISPR-induced c.1252C>T point mutation in 293T cells was
attempted a total of four times in order to achieve the correct edit (Table 10). Our first
attempt we used the aforementioned sgRNA and PX459 vector, however, due to technical
difficulties, single colony selection did not produce many viable transfected clones and
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few that survived did not contain the edit upon sequencing. All sequences revealed
ambiguous base-calling, after PAM cut site. One of those clones revealed wild-type at
variant nucleotide. Two out of three sequences revealed an incorrect PAM edit: CCC to
CGC, and the other CCC to GCC (Appendix A).
The second attempt did not include any changes to the sgRNA; however,
technique optimization of the single colony selection improved survival of clones. More
clones (32 experimental, and 5 control clones) were harvested and, based on PCR clone
selection, ten experimental and one control were sequenced. Sequence results of
experimental clones revealed all sequences were wild-type (Appendix B). However,
some of the clones contained the silent PAM mutation. The 5’ end of sequences were
fairly clean, until downstream the Cas9 cut site, where some sequences revealed
ambiguous base calling, indicating the target site was cut, but repair introduced INDELS
and other mutations. The control clone revealed wild-type at variant nucleotide and the
PAM sequence, as expected.
Because sgRNA-dual-nickase approach has been shown to be more efficient at
on-target CRISPR genome editing than sgRNA (Gopalappa et al. 2018), the third
CRISPR attempt included the use of the original sgRNA, and a second sgRNA (“dual
nickase”) targeting nearer to the variant nucleotide. Both original and dual nickase
sgRNA were cloned into a new vector (PX462) that contained D10A Cas9 mutation,
allowing for a single stranded cut from each sgRNA-Cas9 construct. Single colony
selection was again successful, with 53 experimental clones, and 12 control clones. After
initial screening by PCR for confirmation of a single amplicon of correct size, six
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experimental clones and one control clone were sequenced. Sequence results revealed all
clones remained wild-type at the variant nucleotide, except for one clone (#10) that
contained the desired edit on the reverse strand (Appendix C). All sequences contained
ambiguous base calling between the 5’ PAM and the variant nucleotide. It is also likely
that a mixed population of transfected HEK cells was obtained during initial single
colony selection, as this is an inefficient process even though optimization of technique
improved harvest. The purified PCR product of clone # 10 was later subcloned to
determine if there were mixed alleles. Sequence results of subcloning revealed sequences
from a mixed cell population due to more than two alleles. (Appendix D). Only one of the
six experimental clone sequences contained the correct “CCC” to “CAC” PAM edit, the
rest did not (Appendix E). The control clone sequence revealed a clean (non-ambiguous
base calling) sequence with wild-type variant nucleotide and no PAM edit, as expected
(Appendix F). BLAST analysis on the control sequence revealed 99% homology to wildtype human ADCY5 exon II.
The fourth and final CRISPR attempt was optimized based on the observation of
previous attempt #2, where the PAM edit was made with minimal to no off-targeting
effects, even though the variant nucleotide was not editing. It seemed likely that the clean
PAM edit was due to the cut site’s proximity to the repair site, in this case the PAM
repair was made because the cut site was only two nucleotides upstream. Therefore, for
the last CRISPR attempt, the second sgRNA that we designed for dual nickase was
cloned into the original vector (PX459), allowing for a double stranded break in closer
proximity to the variant nucleotide. This second sgRNA-Cas9 made the cut 20 bp
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upstream this time, as opposed to 65 bp upstream as in our second attempt. Single colony
selection was the most efficient this fourth attempt, with the initial selection of 300
clones. A total of 43 clones (39 experimental and 4 control) were used to harvest genomic
DNA. PCR screening was performed on all 39 experimental clones, and 4 control clones
(two from each replicate of the initial empty-vector transfection controls, and one nontransfected control). PCR results revealed a high success of single PCR product of correct
size (Appendix G). Of the 39 experimental clones, 37 were sequenced, along with control
clones, and one non-transfected control. Sequence chromatograms revealed various edits
of the variant nucleotide, with some clone sequences that contained a c.1252C>G edit, as
well as other mutations, there were some that remained wild-type, and some had too
many ambiguous base-calls to read the sequence accurately (Appendix H). Successfully,
there were two sequences (#13 and #36) that contained the correct c.1252C>T edit in the
forward strand (Appendix I). However, these two sequences also contained other nonsilent mutations directly upstream and downstream the variant nucleotide. None
contained the PAM edit, as expected because the new cut site is just 5’ to the new PAM
sequence, which is downstream the original PAM sequence (Appendix J). All control
clones contained wild-type sequences as expected. BLAST analysis of control clones
showed 99 percent identical to wild-type (Appendix K).
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DISCUSSION

Dopamine-Containing Differentiation

I have demonstrated through directed differentiation of mouse embryonic stem
cells that db-cAMP treatment in vitro does in fact affect total cell numbers as well as
percentage of cells that undergo neuronal differentiation. Based on the average DAPI
count, our experiments reveal an overall increasing trend of total cell population starting
from no treatment up 1400 µM and 2800 µM treatment. This suggests that increased
cAMP during differentiation affects either non-neuronal cell differentiation or survival,
yet without the dramatic drop in cell count at higher the cAMP treatments, as we see with
neuronal cell type. This difference in the trend of cell count between non-neuronal and
neuronal cell types indicates increased cAMP influences general cell numbers, but its
distinct effect is also cell-type specific.
Amongst treatment levels of db-cAMP, we also observed an effect on the
neuronal morphology and number, represented by Tuj1 positive cells, out of the total cell
population (DAPI count). As reported in the results, ICC visually reveals that with
increasing db-cAMP concentrations, there is a continual change in neuronal arrangement.
There seems to be a threshold for producing changes in neuronal presentation, with a
dense presentation of bundles of neuronal processes in the no treatment and 700 µM, to a
striking decrease in neuronal density with the higher cAMP treatments (indicated by a
loss of TH or Tuj 1 signal). We even see a continual change from 1400 µM to 2800 µM,
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where not only are neurons the sparsest, but visually, the fluorescent signal of the somata
become more prominent. This visual pattern we see is reflected in the quantification of
neurons (Tuj1 positive cells) out of total cell population amongst treatments; there is an
initial increase in percent Tuj1 positive cells with 700 µM treatment, then a tapering
down at the higher cAMP levels. The biological interpretation of the effect that higher
cAMP has on the neuronal cell population is that during early development, a gain-offunction mutation in ADCY5 is likely to affect the initial production of neurons, long
before it may influence differentiation of these neurons to specific neuronal cell type,
such as dopaminergic.
Examining the effects of db-cAMP treatment on dopamine-containing
differentiation, represented by TH positive cells, out of the total cell population (DAPI
count), we see the same visual pattern on ICC as we do with the Tuj1 cells. The no
treatment controls display bright, clustered TH positive neurons, with a subtle increase in
TH signal in the 700 µM merge image, then we start to lose TH signal in the 1400 µM,
and then only a small amount of distinct TH signal present with 2800 µM, where
projections are sparse. Quantitative analysis of TH count divided by DAPI count,
yielding percent TH positive cells, confirms ICC results, and mimics the percent Tuj1
positive cells’ pattern: a slight increase in percent with the 700 µM treatment, and then
tapers down in 1400 µM and continued in 2800 µM db-cAMP.
Because the percent TH positive cells out of DAPI count results followed the
pattern of results obtained for percent Tuj 1 out of DAPI, we suspected that the increase
in percent TH population seen at 700 µM may just be due to the increase in overall
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neuron count (Tuj1). We addressed this by dividing TH cells by Tuj1 cells, which
removed DAPI background and allowed for TH to Tuj1 ratio. As reported in the results
section, the percent TH out of total neuron population (Tuj1) was negligible and not
statistically significant. Therefore, we concluded that cAMP does not affect the percent
dopamine-containing differentiation efficiency, but rather affects neuronal differentiation.
This information ties back to what was stated earlier in this discussion, that higher levels
cAMP during early development could affect neuronal cell type, prior to neuron-specific
differentiation. Specifically, the process of neurogenesis starts with exuberant neural
progenitor cell production (NPC), followed by migration, differentiation, synaptogenesis,
selective apoptosis, myelination for select neurons, and finally synaptic pruning.
However, many neurons remain non-myelinated. (reviewed in Kristiansen M, and Ham J.
2014).
Other studies that have included cAMP treatment during cell culture include
research by Branton et al. 1998, where they demonstrated that treatment with db-cAMP,
ranging from 500 µM to 1000 µM of a cell suspension made from rat embryonic ventral
mesencephalon, , showed a dramatic increase of TH positive cell survival at the 700 µM
level, and then a gradual decrease above 700 µM concentration. This coincides with the
threshold effect we see in our experiments with cAMP treatment, from an increase in
neuronal production at lower concentrations, to a decrease in higher levels. However,
that study did not include a general neuronal cell marker such as Tuj1. It is likely that the
pattern that they are describing could be due to an overall increase in general neuron
population, as we determined in our study. In a different study by Rolletschek et al. 2001,
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they report the addition of survival promoting factors that included 700 µM db-cAMP,
during in vitro differentiation of mESCs to dopaminergic neurons, produced an increase
in the percentage of cells, expressing TH mRNA, with an upregulation from 9 percent (on
day 4) to 76 percent (on day 16). Also, in a genome-wide profiling study of dopaminergic
differentiation of hESC (Momĉilović et al. 2014), cAMP synthesis was identified as one
of the upregulated pathways, and they demonstrated that the addition of 200 µM dbcAMP during in vitro dopaminergic differentiation increased DA neuron yield by 5 %. In
an earlier study by Michel and Agid, 1996, found that the addition of db-cAMP
specifically promotes dopaminergic development, but not GABAergic, or serotonergic
neurons.
As previously described, the study by Chen et. al 2014 showed that exogenous
overexpression of ADCY5 p.R418W mutation increased cAMP production, above wildtype levels, in pharmacologically activated 293T cells, using beta-adrenergic agonists,
forskolin and isoproterenol. In fact, they demonstrated an almost 10-fold increase in
cAMP production, compared no treatment cells, as measured by ELISA. Combining this
key information with our results that demonstrate cAMP treatment affects the overall
production of neurons and altered neuronal morphology, with the knowledge that
ADCY5 is expression in the striatum increases dramatically during early development
(Menacci et al. 2015), it is not surprising that neurogenesis during early development
could be dramatically altered at any of those stages. It is likely that the decreased
neuronal cell production and changes in morphology would ultimately affect
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synaptogenesis, where initial cell density is crucial in determining selective apoptosis
(Kristiansen and Ham 2014).
Based on the above information, one could predict that a higher level of cAMP
during early development could result in the ADCY5 disease phenotype. However, it is
not known what the actual cAMP concentrations are in ADCY5-related dyskinesia
patients, or if there are varying cAMP concentrations amongst patients, but this could
account for the wide spectrum of clinical presentations.
Other possible effects of increased cAMP levels by mutated ADCY5 may include
disruption of the other components of dopamine signaling, specifically dopamine
receptor expression and enzymes responsible for dopamine synthesis. Data derived from
experiments conducted by Linh Pham (unpublished data 2018) seem to support this
hypothesis. Linh looked at the effect 1400 µM db-cAMP on the protein expression of
dopaminergic receptor (D2R) and tyrosine hydroxylase (Figure 13) (Table 11).
Immunoblot analysis revealed an approximately 2-fold increase of D2R in the cytosol as
well as in the membrane of the neurons differentiated in the presence of 1400 µM dbcAMP. It has been reported that “D1 and D2 receptors express distinct patterns of
affinity to dopamine and interact differently with one another depending on synaptic
concentrations of neurotransmitter” (reviewed in Korchounov et al. 2010). In fact, “while
both D1 and D2 receptors are abundant in the striatum, the expression pattern of D1 and
D2 receptors in the axon terminals, dendrites, and spines are obviously diﬀ erent by
electron microscopic analysis” (reviewed in Hisahara and Shimohama 2011). Because the
D2 subtype, including D3 and D4, are coupled to inhibitory G-proteins that inhibit cAMP
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production, this provides a theoretical basis to suspect that an increase in D2 postsynaptic
expression would disrupt the cAMP downstream substrates such as DARPP-32, that
modulate other neurotransmitters (reviewed in Hisahara and Shimohama 2011).
Looking at TH protein expression levels, there was 1.15-fold increase in
cytosolic TH expression and a 2.5-fold reduction in membrane TH expression in neurons
differentiated in the presence of 1400 µM db-cAMP when compared to no treatment. As
a control, the results also reveal no TH expression present in mESCs or HEK 293T cells,
which supports that TH expression is associated with dopamine-containing neuronal
differentiation. The change in TH expression coincides with our finding that 1400 µM
db-cAMP treatment causes an overall decrease in the neuronal cell population. With
fewer neurons present, it is not surprising that the immunoblot analysis displayed less TH
protein in the membrane fraction due to fewer available neurons, not necessarily less TH
production per neuron.
Of relevance to this data interpretation is the biochemical regulation of
dopaminergic signaling. Dopamine neurotransmitter is packaged in vesicles at the
presynaptic axon terminal, and upon calcium influx, are released into the synaptic cleft.
Excess dopamine is recycled back to the presynaptic terminal (reviewed in Daubner et al.
2011).
Tyrosine hydroxylase is the rate-limiting enzyme in the conversion of tyrosine to
L-DOPA. Looking at cellular localization of TH expression in vivo, studies have shown
that TH is primarily expressed in the soma cytosol, but also in the membranes of the
axons and dendrites, differing in its subcellular distribution (reviewed in Pickel et al.
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1975). Within the soma, TH is expressed in the membranes of the Golgi apparatus, the
endoplasmic reticulum, and is soluble throughout the cytoplasm, but not found in the
mitochondrial or lysosomal membranes. Within the processes, TH staining revealed
organized, linear aggregates that were parallel along the length of the plasma membrane
(reviewed in Pickel et al. 1975).
The enzymatic activity of tyrosine hydroxylase is inhibited by a dopamine
feedback loop. TH is phospho-activated by PKA (directly downstream cAMP), and in
turn, this phosphorylation makes TH less susceptible to the feedback inhibition loop.
Studies also revealed that TH is associated with regulatory proteins, such as PP2A and
AADC, forming complexes that aid TH proximity to secretory vesicles, allowing for
quick availability of dopamine transport to vesicles (reviewed in Daubner et al. 2011).
The upregulation of the inhibitory D2 receptor coupled with the 2.5-fold decrease
of TH in the membrane fraction of neurons differentiated in the presence of db-cAMP
(which includes the endomembrane compartments necessary for dopamine secretion),
suggests dopamine signaling is compromised in neurons exposed to high levels of cAMP.
Though there was no significant change of TH expression in the cytosol (1.15-fold), this
doesn’t necessarily mean this population of enzymes would not be impacted by increases
in endogenous cAMP, as inhibition of enzymatic activity would not be detected by
immunoblot. To explore this as a mechanism related to ADCY5-dyskinesia, we would
have to repeat these experiments and perform TH enzymatic assays with protein extracts
from both wild type and ADCY5 mutant cells.

66
These data suggest that an increase in cAMP may not just affect number of
neurons produced during early development, which not only would affect connectivity,
but also the amount of available D2R receptors in the cytosol and membrane. The change
in availability of dopamine receptors, will inevitably affect ion channel permeability upon
dopamine binding, ultimately affecting neuron firing (Girault JA, and Greengard P.
2004). The work conducted by Linh Pham (2018) contributes to this project; however, it
is important to take into the consideration the limitations of those experiments. The
protocol used to extract membrane proteins, may not have been specific to cell membrane
fraction, but might also include intracellular organelle membranes. If experiments were
repeated, it would be important to use a cell membrane specific extraction protocol as
well as include a cell surface specific marker in immunoblot analysis, and even an
endomembrane marker to ensure we are not getting significant amounts of organelle
membrane. Examining the D1 subclass receptor protein expression under cAMP
conditions would also be beneficial because of its role in increasing membrane potential.
If increased cAMP during early development affects dopamine inhibitory receptor
protein expression, then a plausible treatment may include D2 receptor antagonists to
inhibit overproduction, or D1 receptor agonists as a compensatory treatment option;
however, this option is limited because cells will often adjust receptor expression in
response to exogenous drug treatment. In fact, DA excitatory receptor agonists may be an
optimal choice because “DA receptor agonists exert their pharmacologic eﬀ ect by
directly activating DA receptors, bypassing the presynaptic synthesis of DA” (reviewed
in Hisahara and Shimohama 2011).
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When considering treatment for ADCY5 patients, it is important to note that two
other movement disorders that result from disrupted dopaminergic signaling, Parkinson’s
(PD) and Huntington’s (HT) diseases differ in their presentation compared to ADCY5related dyskinesia (AD) patients. Both PD and HT have a much later onset in adulthood
than AD patients, which can present with symptoms as early as six months of age
(Menacci et al. 2015). AD patients do not usually experience cognitive defects, as is
common with both PD and HT. PD is more associated with bradykinesia and akinesia
and can display dementia as the disease progresses. Although HT and AD both
experience dystonia, chorea, and dysarthria, AD patients are mostly affected by
involuntary movements, whereas HT patients also experience impaired voluntary
movement (Chen et al. 2015; Mayo Clinic 2018). It has also been reported that a unique
symptom of AD is myokymia (Menacci et al. 2015), whereas a unique feature of PD is
tremor (reviewed in Hisahara S, and Himohama 2011). Looking at the cellular level,
another key difference is that PD has been characterized as a loss of kinesis function due
to loss of midbrain dopaminergic neurons (reviewed in Hisahara S, and Himohama
2011). Only about 15 percent of PD patients have been linked to genetic mutations in
LRRK2, PARK7, PINK1, PRKN, or SNCA, as well as other genes not listed here, but
most cases are sporadic (NCBI 2012). HT is caused by an autosomal dominant genetic
mutation in the HTT gene that causes loss of striatal neurons (Mayo Clinic 2018).
Knowing how AD’s clinical presentation is distinguished from other movement disorders
and combining this knowledge with our investigation of this disease at the
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cellular/molecular level, unique treatment options and timing of treatment can be
customized, maximizing patient care.
The findings of this research allow for collaborators to make informed decisions
about therapeutic options, specifically narrowing the selection of pharmacologic
treatments, such as an ADCY5 isoform-specific inhibitor (Chen YZ et al. 2014; reviewed
in Hurley 1999), or cAMP-specific PDE 4, 7, or 8 agonist (reviewed in Raker 2016) to
increase degradation of cAMP. These drug treatments can be tested first on patient iPSCs
for efficiency of elimination of excess cAMP, before going to clinical trials, minimizing
the unnecessary trial and error on actual patients. These patient iPSCs will be critical in
narrowing the gap between benchtop to bedside treatment. Individual patient genomic
DNA can be used to perform exome sequencing to determine mutation-type, followed by
creation of patient iPSCs, which will allow scientists to perform experiments tailored to
individual patients, testing highly selected pharmacologics to determine efficacy and
appropriate dosage.

CRISPR-Induced Point Mutation

Our first attempt failed due to inefficient single clone selection, and sequence
results revealed that our sample was most likely from a mixed population of cells, as
opposed to monoclonal. In our second attempt, single clone selection was much more
efficient due to technique optimization, however sequence results all wild-type at variant
nucleotide, and some correct editing of the PAM sequence. There were also other
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mutations and INDELS created. In the third attempt, a dual nickase approach was used in
hopes to increase efficient repair sequence results revealed mostly wild-type, with other
mutations, including INDELS.
By learning from previous attempts, we optimized the final attempt by designing
a sgRNA that would target closer to the variant nucleotide, in hopes to increase repair
efficiency We successfully edited the variant nucleotide of interest in two transfected
HEK clones out of 37 experimental clones sequenced; we were unsuccessful in making
that our only edit. In fact, every sequence examined contained non-silent mutations. This
is not surprising as CRISPR is known for high targeting efficiency but inefficient repair
(reviewed in Paix et al. 2017; Aird, et al. 2018). In fact, single nucleotide edits have a low
efficiency of 0.1 percent 5 percent (Komor, et al 2016). In all four attempts, we
demonstrated that our sgRNA design found its target site and a cut was made, but with
low repair efficiency. The fourth attempt was by far the most successful, however still
needs more optimization to limit off-target mutations. This optimization can be
accomplished by understanding the full capabilities of CRISPR technology and learning
from what other scientists have done to optimize their CRISPR experiments.
CRISPR made its formal debut in 2012 (Jinek et al. 2012), and since then its use
and breadth of application has accelerated dramatically in the field of research (reviewed
in Hsu et al. 2014). Some of the initial obstacles with CRISPR included inefficient
delivery by plasmid or viral vectors, which in turn can lead to overexpression of the
vector, producing off-targeting editing (reviewed in Jacobi A 2017). CRISPR initially
was limited to the subtype II Cas9 endonucleases, but recent developments have provided
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a wider array of Cas9 endonucleases from subtypes I and II, and now with genetically
engineered Cas nucleases, researchers can use enzymatically inactivated, or “dead” Cas9
(dCas9), fused with a transcriptional activator or inhibitor to allow for binding of Cas9sgRNA complex, without cutting. The tethered dCas9 can therefore be used for gene
activation or inhibition, or even epigenetic applications (reviewed in Hsu et al. 2014).
A common limitation to CRISPR editing is low efficiency of homology directed
repair (Aird, et al. 2018). Because the enzymatic activity of CRISPR endonucleases can
stimulate the host cell’s NHEJ as well as HDR, this increases likelihood of getting
nucleotide insertions and deletions, known as INDELS (reviewed in Hsu et al. 2014).
From my own observations using CRISPR, it also seems likely to get off target editing,
including INDELS and point mutations, based on how close the edit site is to the cut site.
As seen in our initial attempts, the further downstream the edit site is to the initial cut
site, the more likely of getting other editing events such as point mutations and INDELS.
Our final CRISPR experimental design included a cut site that had greater proximity to
the repair site, much closer than previous sgRNA-transfection attempts. This indeed
improved our editing efficiency, as it was the only time we achieved the correct edit of
the variant nucleotide, but still it created other off target, non-silent mutations. It is also
probably that once edited, using the repair template, there are still mutations naturally
occurring within the HEK 293T genome, not induced by the sgRNA transfection. Other
researchers using CRISPR have circumvented the low repair efficiency by optimizing
CRISPR design as well, using novel techniques. A recent study by Aird, et al. 2018 used
covalent tethering of the single-stranded DNA repair template directly to the Cas9-
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sgRNA ribonucleoprotein complex (non-vector delivery), to ensure presence of repair
template in proximity to cut site. As reviewed in other literature, this approach has been
shown to decrease the risk of an immune response from the host cell, increases the
stability of the Cas nuclease, and limits the Cas9 components: allowing quick termination
of cutting once the edit has been made. This thereby limits the off-targeting effects
compared to vector delivery (reviewed in Jacobi A 2017). Referencing back to the Aird,
et al 2018 study, their results demonstrated increased efficiency in different target loci of
multiple cell types, with a 5 to 11-fold increase in HDR efficiency. They also confirmed
efficiency at the gene expression level, using qPCR, and found a 2-fold increase in HDR
efficiency using the tethered repair oligo method, compared to untethered Cas9.
Another approach that may improve precise editing is base editing, a modified
CRISPR technique to create a point mutation within the genome without creating a
double-stranded break, and conversion is deemed irreversible. (Komor et al. 2016). Base
editing makes use of dCas9, fused to a cytidine deaminase enzyme, allowing for direct
conversion of cytidine to uridine (essentially a C to T, or G to A transition mutations).
This conversion can take place within five nucleotides of target binding. Research at the
University of Harvard, Liu lab, has successfully demonstrated this base editing using four
human and murine cell lines, with “permanent correction of approximately 15 percent to
75 percent of total cellular DNA with minimal (typically ≤1 percent) INDEL formation”
(Komor et al. 2016).
Moving forward with the CRISPR portion of this project, future work could
include: 1). A ribonucleoprotein sgRNA-Cas9 delivery. 2). Design of allele specific
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primers for initial PCR confirmation of edit, for more specificity. 3). A base editing
approach could be tried as an alternative to traditional CRISPR. Once a monoclonal cell
line with the desired edit has been created, it would critical to then perform and optimize
ELISA to quantify cAMP levels produced under mutant conditions compared to wildtype. Repeating this experiment in multiple cell lines would also be beneficial. This data
could then be compared to not only the gain-of-function experiments first conducted by
Chen et al. 2014, but also to compare with the levels of cAMP that produced changes in
our neuronal differentiation experiment. If these cAMP levels were found comparable to
the changes we saw in our neuronal differentiation experiments, this would support the
hypothesis that the p.R418W mutation is likely a gain-of-function mutation, and a more
definitive biological conclusion could be made about the effects of increased cAMP on
cellular function and early development.
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CONCLUSIONS

The data analyzed from our neuronal differentiation experiments provide a base
model for understanding the pathophysiological mechanisms underlying the ADCY5related dyskinesia phenotype. We demonstrated that cAMP levels above 700 µM do not
significantly affect dopamine-containing neuronal specific differentiation, however it
does significantly decrease overall neuronal cell type production, as well as change
neuronal morphology. Our data supports a model where the molecular basis of ADCY5related dyskinesia precipitates its effects during early development by altering the
morphological structure of neuron fascicles and decreasing overall neuron production,
before differentiation of those neurons take place, and thereby ultimately affecting
neuronal connectivity and proper signaling. Based on Linh Pham’s data, we also propose
that downstream effects of high levels of cAMP include increased D2 protein expression
levels, and decreased levels of the dopamine-synthesizing enzyme, tyrosine hydroxylase,
within the membrane of neuronal processes, ultimately disrupting the balance of the
striatonigral dopamine pathway.
Building upon our model, further investigation will require looking at other
downstream effects of high levels of cAMP, such as excitatory D1 subtype receptors,
regulation of CREB, and neurotrophic factors, NGF, PACAP, BDNF, and DARRP-32.
Our findings are significant when we consider the spatiotemporal gradient of neuronal
development, and ADCY5 expression. Because the striatonigral dopaminergic pathway
travels through to the striatum and activates ADCY5 all through early development and
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long after birth into adulthood, the expansive time frame for deleterious effects of
mutated ADCY5, enriched in the striatum, provides probable cause for the broad
spectrum of clinical presentation of ADCY5-related dyskinesia.
Unfortunately we are not able to compare the levels of db-cAMP that affect
neuronal differentiation to levels of endogenous cAMP in cells containing the p.R418W
mutation. Although not completed according to our initial aims, the CRISPR portion of
this research will still provide a starting point for future optimization of a CRISPR-based
assay that will be useful to our collaborators in understanding the cellular effects of not
only the p.R418W mutation; it will also allow for a directed plan for analysis of the other
17 point mutations known to date. The results of these assays, specifically the quantified
cAMP under each mutation type, can then be used as a baseline to compare to ADCY5related dyskinesia patient samples. Patient samples will allow for their iPSCs to be used
to perform ELISA to quantify individual levels of cAMP, comparing them to nonaffected individuals as well as other patients with the same mutation, and patients with
other ADCY5 mutations, ultimately expanding the database of knowledge about the
molecular basis of ADCY5-related dyskinesia so treatment can be improved.
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APPENDICES

Appendix A: CRISPR attempt # 1 revealed mixed sequence results and no c.1252C>T edit
made. A. Chromatogram of clone 2B reveals wrong PAM edit (from CCC to GCC). B.
Chromatogram of clone 2B reveals ambiguous base calling for most of sequence, but detectable
wild-type at variant nucleotide (blue highlight).

A). PAM sequence

B). Variant nucleotide
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Appendix B: CRISPR attempt # 2 revealed no edit made to variant nucleotide. Example of
partial chromatogram of sequence results from CRISPR attempt #2. A). Clone # 1 sequence
revealed wild-type at variant nucleotide (blue highlight). B). Clone # 1 also contained wild-type
PAM sequence (blue highlight). C). Clone # 2 revealed a c.1252C>G edit (blue highlight). D).
Clone # 6 revealed correct PAM edit from CCC to CAC (blue highlight). E). Empty-vector
transfected control clone revealed wild-type at variant nucleotide (blue highlight). F). Emptyvector transfected control clone revealed wild-type at PAM sequence as well (blue highlight).

A).

B).
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C).

D).
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E).

F).
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Appendix C: CRISPR attempt # 3 sequence results revealed mixed edits made. Example of
partial chromatogram of sequence results from CRISPR attempt #3. A). Chromatogram of clone #
4 forward sequence revealed wild-type (blue highlighted C). B). Chromatogram of clone # 10
forward sequence revealed c.1252C>A edit (blue highlight), and the reverse sequence reveals
c.1252G>T edit (blue highlight). C). BLAST analysis of wild-type sequence (query) vs. forward
and reverse strand of clone 10 sequence (subject) revealed clone 10 sequence is 98% identical to
only a portion of the wild-type sequence.

A).

B). Forward
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Reverse

C). Forward strand BLAST
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D). Reverse strand BLAST
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Appendix D: CRISPR attempt # 3. subcloning of transfected HEK clone #10 reveals mixed
alleles A). Forward and Reverse sequence of one subcloned colony reveals a c.1252C>G and
c.1252 G>C edit, respectively (blue highlight). B). Forward and Reverse sequence of a second
subcloned colony reveals wild-type at variant nucleotide (blue-highlight).

A). Forward

Reverse
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B). Forward

Reverse

91

Appendix E: CRISPR attempt # 3 results reveal only one sequence contained correct PAM
edit. A). Clone # 4 reveals no edit made to PAM (blue highlight). B). Clone # 44 contains the
silent mutation edit “CCC” to “CAC” (blue highlight).

A).

B).
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Appendix F: CRISPR attempt # 3. Sequence results of empty- vector-control clone reveal
wild-type sequence. A). Control clone # 44 sequence results revealed wild-type sequence at
PAM (blue highlight). B). Control clone # 44 sequence also revealed wild-type at variant
nucleotide (blue highlight), as expected.

A). PAM sequence

B). Variant nucleotide
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Appendix G: CRISPR attempt # 4 individual clone PCR confirms correct amplicon size. A).
Gel # 1, labeled with clone #’s. L= O’Gene mix ladder. Top row reveals a single amplicon of
correct size (441 bp) for most clones, except clone # 5 and # 11. B). Gel # 2 reveals all clones
have single amplicon of correct size (441 bp). E=empty lane, C= no DNA control
(contamination), NT=non-transfected HEK control.

A).

B).
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Appendix H: CRISPR attempt # 4 sequence results reveal mixed edits. A). Chromatogram of
clone # 33 forward sequence reveals incorrect c.1252C>G edit. B). Chromatogram of clone # 29
forward sequence reveals wild-type at variant nucleotide. C). Chromatogram of clone #26
forward sequence reveals ambiguous base calling, sequence most likely not monoclonal.

A).

B).
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Appendix I: CRISPR attempt # 4 sequence results reveal 2 clones with edit c.1252C>T
made. A). Clone # 13 sequence, with c.1252C>T edit (blue highlighted T). B). Clone # 36
sequence with c.1252C>T edit (blue highlighted T). C). BLAST of wild-type (query) vs. clone 13
forward sequence (subject) reveals only 89% identical. D). BLAST of wild-type (query) vs. clone
36 forward sequence (subject) reveals 100% identical sequence in only 249 bp of the amplified
region.

A).

B).
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Appendix J: CRISPR attempt # 4. Sequence results reveal PAM edit was not made in any
clone sequences. A). Chromatogram of clone # 13 reveals wild-type at PAM sequence (blue
highlight). B). Chromatogram of clone # 1 reveals wild-type at PAM sequence (blue highlight).

A).

B).
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Appendix K: CRISPR attempt # 4 sequence results reveal control clone is wild-type. A).
Empty-vector transfection control clone # 53 (replicate 1) reveals wild-type sequence. B). Emptyvector transfection control clone # 55 (replicate 2) reveals wild-type sequence. C). Nontransfected control HEK cells reveal wild-type sequence. D). BLAST analysis of wild-type
(query) vs. clone #53 (subject) reveals 99% identical sequence. E). BLAST analysis of wild-type
(query) vs. clone #55 (subject) reveals 99% identical sequence. F). BLAST analysis of wild-type
(query) vs. non-transfected HEK cells (subject) reveals 99% identical sequence.

A).

B).
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